Immunoglobulin fragment F(ab')


Journal

Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699

Informations de publication

Date de publication:
10 2020
Historique:
received: 15 05 2020
revised: 28 06 2020
accepted: 30 06 2020
pubmed: 14 7 2020
medline: 27 10 2020
entrez: 14 7 2020
Statut: ppublish

Résumé

COVID-19, which is caused by the emerging human coronavirus SARS-CoV-2, has become a global pandemic that poses a serious threat to human health. To date, no vaccines or specific antiviral drugs have been approved for the treatment of this disease in clinic. Herein, therapeutic antibodies for SARS-CoV-2 were obtained from hyperimmune equine plasma. First, a recombinant SARS-CoV-2 spike protein receptor-binding domain (RBD) was obtained in gram-level quantities through high-cell density fermentation of Chinese hamster ovary cells. Then, the binding of the RBD to the SARS-CoV-2 receptor, human angiotensin-converting enzyme 2, was verified by several biochemical methods. The efficacy of the RBD in triggering antibody response in vivo was subsequently tested in both mice and equines, and the results showed that the RBD triggered high-titer neutralizing antibody production in vivo. Immunoglobulin F(ab')

Identifiants

pubmed: 32659292
pii: S0166-3542(20)30282-5
doi: 10.1016/j.antiviral.2020.104868
pmc: PMC7351055
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
F(ab')2 receptor 0
Receptors, Immunologic 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104868

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Références

Transfusion. 2005 Jul;45(7):1160-4
pubmed: 15987362
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Virol Sin. 2018 Apr;33(2):201-204
pubmed: 29541941
PLoS Negl Trop Dis. 2016 Apr 08;10(4):e0004565
pubmed: 27058956
Antiviral Res. 2018 Aug;156:21-28
pubmed: 29870772
PLoS Med. 2006 Jul;3(7):e237
pubmed: 16796401
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
Cell Mol Immunol. 2020 Jun;17(6):613-620
pubmed: 32203189
Science. 2017 Jun 2;356(6341):923-928
pubmed: 28572385
Lancet Infect Dis. 2015 Mar;15(3):285-92
pubmed: 25662592
Virology. 2009 Oct 10;393(1):144-50
pubmed: 19683779
J Hepatol. 2019 Aug;71(2):434-438
pubmed: 31075322
Cell Mol Immunol. 2020 May;17(5):536-538
pubmed: 32132669
Presse Med. 1986 Dec 20;15(45):2239-42
pubmed: 2949253
J Virol. 1990 Jan;64(1):113-9
pubmed: 2152808
Emerg Microbes Infect. 2020 Dec;9(1):382-385
pubmed: 32065055
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Emerg Microbes Infect. 2020 Dec;9(1):275-277
pubmed: 32005086
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Vox Sang. 2020 Aug;115(6):488-494
pubmed: 32240545
J Med Virol. 2020 Jun;92(6):540-545
pubmed: 32108352
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Virol J. 2014 May 06;11:82
pubmed: 24885320
Hong Kong Med J. 2012 Feb;18 Suppl 2:31-6
pubmed: 22311359
Nature. 2016 Dec 15;540(7633):443-447
pubmed: 27819683
Antiviral Res. 2020 Feb;174:104666
pubmed: 31760108
J Virol. 2019 Feb 19;93(5):
pubmed: 30541860
Virology. 2016 Dec;499:375-382
pubmed: 27750111
Vox Sang. 2020 Oct;115(7):545-547
pubmed: 32240549
EBioMedicine. 2017 May;19:119-127
pubmed: 28408242
Clin Infect Dis. 2015 Aug 15;61(4):496-502
pubmed: 25904375
Acta Pharmacol Sin. 2005 Dec;26(12):1479-84
pubmed: 16297347
Virology. 2000 Jul 20;273(1):52-9
pubmed: 10891407
N Engl J Med. 2007 Oct 4;357(14):1450-1
pubmed: 17914053
PLoS Pathog. 2018 Aug 13;14(8):e1007236
pubmed: 30102747
Expert Opin Drug Discov. 2019 Apr;14(4):397-412
pubmed: 30849247
PLoS Pathog. 2014 Oct 02;10(10):e1004386
pubmed: 25275316
DNA Cell Biol. 2004 Jun;23(6):391-4
pubmed: 15231072
J Infect Dis. 2018 Jul 13;218(4):555-562
pubmed: 29659889
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Science. 2016 Mar 18;351(6279):1339-42
pubmed: 26917593

Auteurs

Xiaoyan Pan (X)

State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.

Pengfei Zhou (P)

Wuhan YZY Biopharma Co., Ltd, Wuhan, 430075, China.

Tiejiong Fan (T)

Shanghai Serum Bio-technology Co., Ltd, Shanghai, 201701, China.

Yan Wu (Y)

State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.

Jing Zhang (J)

Wuhan YZY Biopharma Co., Ltd, Wuhan, 430075, China.

Xiaoyue Shi (X)

Shanghai Serum Bio-technology Co., Ltd, Shanghai, 201701, China.

Weijuan Shang (W)

State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.

Lijuan Fang (L)

Wuhan YZY Biopharma Co., Ltd, Wuhan, 430075, China.

Xiaming Jiang (X)

State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China; University of the Chinese Academy of Sciences, Beijing, 100039, China.

Jian Shi (J)

Wuhan YZY Biopharma Co., Ltd, Wuhan, 430075, China.

Yuan Sun (Y)

State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China; University of the Chinese Academy of Sciences, Beijing, 100039, China.

Shaojuan Zhao (S)

University of the Chinese Academy of Sciences, Beijing, 100039, China; CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.

Rui Gong (R)

CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.

Ze Chen (Z)

Shanghai Serum Bio-technology Co., Ltd, Shanghai, 201701, China. Electronic address: chenze2005@hotmail.com.

Gengfu Xiao (G)

State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China; University of the Chinese Academy of Sciences, Beijing, 100039, China. Electronic address: xiaogf@wh.iov.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH